Inventiva S.A.
IVA Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$3.71
KIRA · Stoqly’s AI analyst, in plain words
- Inventiva S.A. had $5.1M of revenue in fiscal 2025, down 49.2% on the year before. Over five years, revenue changed +64.2% a year on average.
- Its operating margin was −3,145.5%, down 2,084.8 pts: of every 100 in sales, about −3,145 is left after running the business.
- Inventiva S.A. lost $399M in fiscal 2025.
- Inventiva S.A. has $46.4M more cash than debt.
Market cap
$693M
P/E
—
Revenue
$5.1M
Net income
−$399M
Free cash flow
—
Operating margin
−3,145.5%
Inventiva S.A. in 30 seconds · fiscal 2025
Are sales growing?
−49.2%
No. Sales fell 49.2% last year.
Does it make a profit?
−7,899.5%
No. It lost money last year.
How healthy are the accounts?
3 / 7
Weak. It passes 3 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Inventiva S.A. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 20-F · Apr 8, 2026
- Legal name
- Inventiva S.A.
- CIK
- 0001756594
Inventiva S.A. · IVA
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $5.0M | $12.8M | $18.9M | $10.0M | $5.1M |
| Revenue growth | 1,069.8% | 158.1% | 47.7% | −47.4% | −49.2% |
| Operating margin | −1,242.6% | −468.9% | −587.7% | −1,060.6% | −3,145.5% |
| Net income | −$58.7M | −$57.0M | −$119M | −$199M | −$399M |
| Net margin | −1,183.5% | −445.6% | −631.8% | −2,002.7% | −7,899.5% |
| Diluted EPS | −$1.50 | −$1.38 | −$2.63 | −$3.33 | −$2.14 |
| Cash | |||||
| Cash from operations | −$56.3M | −$47.2M | −$88.3M | −$93.0M | −$118M |
| Share count change | 15.6% | 5.8% | 9.4% | 31.8% | 212.5% |
| Debt and strength | |||||
| Cash and short-term investments | $98.0M | $92.5M | $29.7M | $100M | $117M |
| Debt incl. finance leases | $11.5M | $47.3M | $59.8M | — | $70.3M |
| Shareholders' equity | $101M | $48.5M | −$35.4M | −$111M | −$33.5M |
| Current ratio | 5.1x | 3.5x | 1.0x | 0.9x | 3.2x |
| Interest coverage | −377.7x | −97.8x | −19.8x | −8.0x | −4.2x |
| Returns and quality | |||||
| Return on capital | −345.8% | −1,420.4% | — | — | — |
| Return on equity | −49.5% | −76.5% | −1,821.8% | — | — |
| Return on tangible equity | −58.8% | −119.1% | — | — | — |
| Piotroski F-score | 2 | 2 | 2 | 1 | 3 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Inventiva S.A. · IVA
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $3.71 a share, the company is worth $693M.
Source: SEC EDGAR XBRL filings (CIK 0001756594). Data updated October 24, 2026. Filed in EUR under IFRS and converted to US$: income and cash-flow lines at each period's average exchange rate, balance-sheet lines at the period-end rate. For information only — not investment advice. Check the original filings before relying on any figure.